vTv Therapeutics (VTVT) Q2 2024 earnings summary

Executive summary

• Clinical-stage pharmaceutical company focused on metabolic and inflammatory diseases, with lead program cadisegliatin for type 1 diabetes currently on FDA clinical hold as of July 26, 2024; first patient screened in pivotal trial before hold.

• Pipeline includes multiple small molecule candidates in various stages, including azeliragon (Orphan Drug Designation for pancreatic cancer) and expanded global licensing for PDE4 inhibitor HPP737.

Financial highlights

• Cash and cash equivalents increased to $45.5 million as of June 30, 2024, up from $9.4 million at year-end 2023, primarily due to a $51.0 million private placement financing.

• Net loss attributable to common shareholders was $5.2 million ($0.81 per share) for Q2 2024, compared to $5.6 million ($2.69 per share) in Q2 2023; six-month net loss was $10.0 million, nearly flat year-over-year.

• Research and development expenses decreased to $3.4 million for Q2 2024, mainly due to lower spending on cadisegliatin.

• General and administrative expenses increased to $3.7 million for Q2 2024, driven by higher share-based compensation, legal, and payroll costs.

• Revenue for Q2 2024 was $1.0 million, recognized from a development milestone under the Newsoara License Agreement.

Outlook and guidance

• Current cash and equivalents expected to fund operations for at least the next twelve months.

• Company plans to resume clinical trials for cadisegliatin after addressing FDA's clinical hold and to initiate additional international studies in 2026; future regulatory submissions anticipated.

• Actively evaluating additional financing and partnering opportunities to support ongoing and future clinical programs.